https://www.selleckchem.com/pr....oducts/alexidine-dih
sure intervention taking such risk factors into consideration, typically in the infantile period. The objective of this study was to carryout a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of the DECLARE-TIMI 58 trial. A discrete event simulation model (Cardiff T2DM) based on the data observed in the DECLARE-TIMI 58 trial was adapted to the Spanish setting to estimate the costs and health
Like
Comment
Share
